
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated strong growth in its reimbursement pipeline, with the number of units rising to 1,669 in the latest quarter compared to 1,611 in the previous quarter, reflecting increasing demand for its myoelectric orthotics. The company is strategically redirecting its focus towards the expanding Medicare market, which is expected to contribute significantly to its revenue, with O&P providers anticipated to comprise approximately 22% of revenue in 2024. Furthermore, a recent favorable ruling from the Centers for Medicare & Medicaid Services has substantially broadened the potential market for the MyoPro device, creating a positive outlook for the company's future financial performance.
Bears say
Myomo Inc. has revised its 2025 revenue guidance downwards, now anticipating $40 to $42 million, a significant decrease from the previous estimate of $50 to $53 million. Additionally, the company's marketing and pipeline performance has been subpar, adversely impacting lead quality and conversion rates, signaling potential challenges in customer acquisition. Furthermore, the authorized insurance backlog has declined consistently, dropping to 208 from 230 in the previous quarter, indicating a weakening demand that may further hinder revenue growth.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares